Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04966585 · ClinicalTrials.gov registry record · Phase 4
Pilot Study of Posaconazole in Crohn's Disease
A Phase 4 study, sponsored by Cedars-Sinai Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT04966585 is a Phase 4 study that was terminated before completion, run by Cedars-Sinai Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT04966585, a Phase 4 study, was terminated before completion, sponsored by Cedars-Sinai Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
This trial is designed to evaluate the effects of oral antifungal treatment with posaconazole on active Crohn's disease (CD) activity and the burden of Malassezia spp. in CD patients with the caspase recruitment domain family member 9 (CARD9) S12N risk allele. Further, this project will investigate the hypothesis that the microbial changes induced by antifungal treatment are associated with dampened downstream immune responses in those with a genetic predisposition to developing strong immune responses to Malassezia.
Interventions
- DRUG Matching Placebo Tablet
- DRUG Posaconazole Delayed Release Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-08-17 |
| Est. Completion | 2025-01-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04966585
The ClinicalTrials.gov registry entry for NCT04966585 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo Tablet is the first listed.
NCT04966585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04966585 about?
NCT04966585 is a clinical study titled "Pilot Study of Posaconazole in Crohn's Disease". This trial is designed to evaluate the effects of oral antifungal treatment with posaconazole on active Crohn's disease (CD) activity and the burden of Malassezia spp. in CD patients with the caspase recruitment domain family member 9 (CARD9) S12N risk allele. Further, this project will investigate ...
What is the current status of trial NCT04966585?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2022-08-17. Estimated completion is 2025-01-22.
What interventions are being tested in trial NCT04966585?
The interventions under investigation include: Matching Placebo Tablet (DRUG), Posaconazole Delayed Release Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT04966585?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.